The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

The Eli Lilly logo sign atop Lilly Biotechnology Center ... Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose weight.

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Eli Lilly's new pill shows impressive results, matching Ozempic in lowering weight and blood sugar levels for diabetes ...

Lilly's phase 3 trial showed that type 2 diabetes patients lost 16 pounds, or nearly 8% of their body weight, over 40 weeks. That compares favorably with Novo's injected drug Ozempic, where ...